Imunon (IMNN) Competitors $0.83 -0.02 (-2.83%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends IMNN vs. CASI, MAAQ, KZR, OMGA, XCUR, ACAB, ESLA, ALRN, VIRI, and CDIOShould you be buying Imunon stock or one of its competitors? The main competitors of Imunon include CASI Pharmaceuticals (CASI), Mana Capital Acquisition (MAAQ), Kezar Life Sciences (KZR), Omega Therapeutics (OMGA), Exicure (XCUR), Atlantic Coastal Acquisition Corp. II (ACAB), Estrella Immunopharma (ESLA), Aileron Therapeutics (ALRN), Virios Therapeutics (VIRI), and Cardio Diagnostics (CDIO). These companies are all part of the "pharmaceutical products" industry. Imunon vs. CASI Pharmaceuticals Mana Capital Acquisition Kezar Life Sciences Omega Therapeutics Exicure Atlantic Coastal Acquisition Corp. II Estrella Immunopharma Aileron Therapeutics Virios Therapeutics Cardio Diagnostics CASI Pharmaceuticals (NASDAQ:CASI) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk, analyst recommendations and community ranking. Is CASI or IMNN more profitable? Imunon has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -143.18%. CASI Pharmaceuticals' return on equity of -181.52% beat Imunon's return on equity.Company Net Margins Return on Equity Return on Assets CASI Pharmaceuticals-143.18% -181.52% -45.72% Imunon N/A -230.05%-128.98% Does the media prefer CASI or IMNN? In the previous week, Imunon had 5 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 5 mentions for Imunon and 0 mentions for CASI Pharmaceuticals. Imunon's average media sentiment score of 0.50 beat CASI Pharmaceuticals' score of 0.00 indicating that Imunon is being referred to more favorably in the news media. Company Overall Sentiment CASI Pharmaceuticals Neutral Imunon Neutral Which has better valuation & earnings, CASI or IMNN? Imunon has lower revenue, but higher earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCASI Pharmaceuticals$22.06M1.86-$26.94M-$2.23-1.19Imunon$500K24.07-$19.51M-$1.89-0.44 Do insiders & institutionals have more ownership in CASI or IMNN? 22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by company insiders. Comparatively, 5.0% of Imunon shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, CASI or IMNN? CASI Pharmaceuticals has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Imunon has a beta of 2.12, indicating that its share price is 112% more volatile than the S&P 500. Do analysts prefer CASI or IMNN? CASI Pharmaceuticals presently has a consensus price target of $6.00, indicating a potential upside of 126.42%. Imunon has a consensus price target of $20.50, indicating a potential upside of 2,369.88%. Given Imunon's stronger consensus rating and higher possible upside, analysts plainly believe Imunon is more favorable than CASI Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Imunon 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Does the MarketBeat Community believe in CASI or IMNN? CASI Pharmaceuticals received 182 more outperform votes than Imunon when rated by MarketBeat users. However, 100.00% of users gave Imunon an outperform vote while only 50.25% of users gave CASI Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCASI PharmaceuticalsOutperform Votes20050.25% Underperform Votes19849.75% ImunonOutperform Votes18100.00% Underperform VotesNo Votes SummaryImunon beats CASI Pharmaceuticals on 13 of the 19 factors compared between the two stocks. Ad Behind the MarketsWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.Click here for the ticker >>> Get Imunon News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMNN vs. The Competition Export to ExcelMetricImunonPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.04M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.4410.5990.1317.20Price / Sales24.07196.061,117.09117.04Price / CashN/A57.1643.1037.85Price / Book0.585.094.784.78Net Income-$19.51M$151.83M$120.31M$225.60M7 Day Performance-1.72%-2.14%-1.92%-1.23%1 Month Performance2.22%-4.56%13.65%0.46%1 Year Performance11.56%8.87%28.34%15.24% Imunon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMNNImunon2.3546 of 5 stars$0.83-2.8%$20.50+2,369.9%+9.2%$12.04M$500,000.00-0.4433Analyst ForecastNews CoverageGap UpCASICASI Pharmaceuticals3.083 of 5 stars$3.15+1.3%$6.00+90.5%-60.4%$48.70M$22.06M-1.39180MAAQMana Capital AcquisitionN/A$5.99-23.2%N/A-55.5%$48.67MN/A0.001Gap UpHigh Trading VolumeKZRKezar Life Sciences3.7081 of 5 stars$6.58-2.5%$40.50+515.5%-24.3%$48.01M$7M-0.5060Analyst ForecastNews CoverageOMGAOmega Therapeutics2.0244 of 5 stars$0.86-11.7%$9.20+974.6%-65.1%$47.40M$3.09M0.00120XCURExicure0.8865 of 5 stars$18.12+4.7%N/A+3,130.1%$47.29M$28.83M-9.2750News CoverageGap UpACABAtlantic Coastal Acquisition Corp. IIN/A$5.77-47.1%N/A-45.7%$47.14MN/A0.004High Trading VolumeESLAEstrella Immunopharma0.1501 of 5 stars$1.27+6.4%N/A-6.5%$45.95MN/A-4.50N/AGap DownALRNAileron Therapeutics3.0747 of 5 stars$2.12-6.2%$19.00+796.2%-41.9%$45.93MN/A-0.699Positive NewsVIRIVirios TherapeuticsN/A$2.36-2.1%$3.00+27.1%+300.7%$45.45MN/A-8.745CDIOCardio Diagnostics2.6517 of 5 stars$1.12-11.1%$2.00+78.6%-58.0%$45.29M$35,688.000.007Gap UpHigh Trading Volume Related Companies and Tools Related Companies CASI Competitors MAAQ Competitors KZR Competitors OMGA Competitors XCUR Competitors ACAB Competitors ESLA Competitors ALRN Competitors VIRI Competitors CDIO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMNN) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMNN Stock Alerts